Among them, S63845 has shown higher affinity than previous MCL-1 inhibitors, displaying a strong anti-MM effect in preclinical studies as a single agent and in combination with venetoclax [23,26]. This evidence concerns the gene MCL1 and Miyoshi myopathy.